Lymphoma Non-Hodgkin
Conditions
Keywords
Non Hodgkin's Lymphomas
Brief summary
The primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients will be determined in the dose escalation/safety evaluation part.
Interventions
Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Sponsors
Bayer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype limited to the following: Follicular lymphoma (FL) grade 1-2-3a Small lymphocytic lymphoma (SLL) with absolute lymphocyte count \< 5 x 109/L at the time of diagnosis and at study entry Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM) Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal) * Relapsed or refractory after ≥ 2 prior lines of therapy (refractory defined as not responding to a standard regimen or progressing within 6 months of the last course of a standard regimen). Patients must have previously received rituximab and alkylating agent(s). * Japanese patients ≥ 20 years of age * ECOG performance status ≤ 2 (Eastern Cooperative Oncology Group:ECOG) * Life expectancy of at least 3 months * Adequate bone marrow, liver and renal function as assessed within 7 days before starting study treatment * Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) for the Institution * Availability of fresh or archival tumor tissue
Exclusion criteria
* Uncontrolled hypertension (blood pressure ≥ 150/90 mmHg, defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg, despite optimal medical management) * Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 (NCI-CTC version 4.0) within 4 weeks of start of study medication (CTCAE: Common Terminology Criteria for Adverse Events, NCI: National Cancer Institute). * History or concurrent condition of interstitial lung disease or severely impaired pulmonary function * Unresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopecia. * Prior treatment with PI3K inhibitors * Systemic corticosteroid therapy (ongoing) * Type I or II diabetes mellitus with HbA1c \> 8.5% or fasting plasma glucose \> 160 mg/dL at Screening * Known history of human immunodeficiency virus (HIV) infection. * Hepatitis B or C requiring treatment * Cytomegalovirus (CMV) PCR positive at baseline * Known lymphomatous involvement of the central nervous system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse Events | Up to 18 months | — |
| Intensity of AE | Up to 18 months | The NCI Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0) will be used to assess the intensity of AE |
| Objective Tumor Response (OR) | Up to 18 Years | OR: Best response rating of complete response or partial response according to the criteria defined in the Revised Response Criteria for Malignant Lymphoma(JClin Oncol.2007 Feb) |
| Recommended dose determined in the dose escalation/safety evaluation | Up to 18 months | — |
Countries
Japan
Outcome results
None listed